Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.
Spirit of Hope - A History of Genzyme 1981-2012
As a pioneer of the biotechnology movement in the early 1980s, Genzyme has always been driven by cutting-edge science and a commitment to developing treatments for unmet medical needs. In this video, CEO David Meeker, former CEO Henri Termeer, and patients share how Genzyme has continued to build on this foundation over the past three decades.
Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with patient communities and listen to their perspectives so that we can truly understand their needs. These collaborations guide us as we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before.
Sanofi Genzyme's dedication to patients extends beyond the development of products. We've initiated numerous free drug, payment assistance, and humanitarian programs to ensure that vital treatment reaches all those who need it.
We're also committed to responsible corporate citizenship: we lead the industry in environmental initiatives and support local communities through grants and our employees’ volunteer efforts.
Learn more about our corporate responsibility efforts
Last Updated: 10/21/2016